Giant cell arteritis, a chronic autoimmune disease of the aorta and its large branches, is complicated by aneurysm formation, dissection, and arterial occlusions. Arterial wall dendritic cells attract CD4 + T cells and macrophages to form prototypic granulomatous infiltrates. Vasculitic lesions contain a diverse array of effector T cells that persist despite corticosteroid therapy and sustain chronic, smoldering vasculitis. Transmural inflammation induces microvascular neoangiogenesis and results in lumen-occlusive intimal hyperplasia. We have examined whether persistent vessel wall inflammation is maintained by lesional T cells, including the newly identified tissue-resident memory T cells, and whether such T cells are sensitive to the cytokine-signaling inhibitor tofacitinib, a Janus kinase (JAK) inhibitor targeting JAK3 and JAK1.
V
asculitides of large elastic arteries are infrequent but potentially fatal diseases, damaging vital blood vessels, such as the aorta, the subclavianaxillary bed, the carotid branches, and mesenteric arteries. Giant cell arteritis (GCA) accounts for most cases of autoimmune large vessel vasculitis, typically causing vision loss, aortic arch syndrome, aortic dissection, and aortic aneurysms. Extravascular GCA, consisting of an intense hepatic acute-phase response, gives rise to highly elevated laboratory markers of inflammation. Whether the hepatic acute-phase response precedes or follows vascular inflammation is unresolved. GCA is a chronic condition, which persists despite long-term therapy with high-dose corticosteroids, 1,2 and disease risk genes have been localized to multiple biological pathways. 3 
CD4
+ T cells and macrophages dominate the transmural lesions of this granulomatous vasculitis. Arterial wall dendritic cells function as gatekeepers and by providing access to invading T cells and macrophages fail to protect the artery's immune privilege. 4, 5 In GCA arteries, wall-resident dendritic cells express low concentrations of the immunoinhibitory ligand PD-L1, disarming the protective PD-1 immune checkpoint. 6, 7 Tissue-infiltrating CD4 + T cells are PD-1 + , yet are highly activated, are nonexhausted, and cover multiple effector functions. Most prominent are tissue T helper (Th) 1 and Th17 cells, but interleukin (IL)-21-and IL-9-producing T cells are also present. 8, 9 Heterogeneous T-cell effector populations in the lesions are indicative of an unopposed T-cell response.
GCA's chronicity suggests a role for tissue-resident memory T cells (T RM ), a recently discovered T-cell lineage residing in tissues, where they provide fast and powerful helper functions. 10 Different from central memory and effector memory T cells, T RM cells receive localizing signals in the tissue niche and do not recirculate to secondary lymphoid organs. Two phenotypic markers, CD69 and CD103 (a receptor recognizing E-cadherin), have been identified. 11 T RM cells in E-cadherin low tissues lacking epithelium possibly express alternative markers, such as type I collagen receptors. Originally considered crucial for rapid antipathogen responses, T RM cells may also drive autoimmune tissue inflammation. 12 Functional heterogeneity, being able to release interferon (IFN)-γ, IL-17, IL-9, and tumor necrosis factor-α, enables the proinflammatory effector functions of T RM cells. 13 Tissue-derived IL-7, IL-15, and transforming growth factor-β are believed to guide T RM recruitment, differentiation, and maintenance. 13 Whether T RM cells are involved in building and sustaining GCA's granulomatous lesions and the arterial wall remodeling process is unknown.
T cells depend on signals through their T-cell receptor, but require input from the cytokine milieu to direct their clonal expansion, persistence, and functional differentiation. Environment-cell communications rely on cytokine signals that trigger the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway. 14 The JAK/STAT signaling pathway has been implicated in cancer cell growth and autoimmunity. 15 Th1 lineage commitment is strictly linked to STAT1-and STAT4-mediated gene induction. 16 STAT3 is considered the master regulator for Th17 cell differentiation. Gene polymorphisms encoding type I cytokine receptors and their signaling elements (IL-23R, IL-12B, JAK2, and STAT3) are linked to inflammatory bowel diseases and psoriasis. 17 STAT4 polymorphisms are associated with rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus. 18, 19 The critical role of JAK/STAT in immune-mediated disease has been therapeutically exploited with the development of JAK inhibitors (Jakinibs), small-molecule inhibitors that block the action of type I/II cytokines. The JAK3/1 inhibitor tofacitinib 20 has been approved for rheumatoid arthritis treatment.
21
JAK3-activating mutations in T-cell acute lymphoblastic leukemia and JAK3-inactivating mutations in severe immunodeficiency emphasize the critical role of JAK3 in T-cell biology. 22, 23 Most prominently, JAK3 inactivation results in the loss of function of the common γ-chain (γc), causing X-linked severe combined immunodeficiency. 23, 24 Cytokines central in regulating T-cell activa-
Clinical Perspective
What Is New?
• Signal transducer and activator of transcription (STAT) 1 and STAT2 target genes, the transcription factors STAT1 and STAT2, and the STAT pathway activators type I and type II interferon are abundant in the tissue transcriptome of arteries with giant cell arteritis.
• The Janus kinase/STAT inhibitor tofacitinib suppresses the ex vivo induction of interferon-γ-positive T cells in patients with giant cell arteritis.
• Chimeric mice carrying human arteries and immune cells from patients with giant cell arteritis develop persistent vasculitis. • In the chimeras, tofacitinib efficiently suppresses T-cell invasion into the artery, inhibits proliferation and cytokine production of vasculitogenic T cells, and curbs survival of artery-resident T cells.
• Tofacitinib treatment prevents neoangiogenesis and intimal hyperplasia in inflamed arteries.
What Are the Clinical Implications?
• The Janus kinase/STAT inhibitor tofacitinib effectively targets multiple disease-relevant processes in inflammatory vasculopathy and represents a potential disease-modifying agent. Chronic GCA requires T cells persisting in the arterial wall to orchestrate macrophage activation, drive inflammation-associated neoangiogenesis, and promote intimal hyperplasia. 26, 27 Current therapies focus on proinflammatory innate cytokines, 28, 29 but fail to eliminate wall-infiltrating T cells. 2 We have explored whether targeting JAK3 with the Jakinib tofacitinib can remove disease-relevant T cells from inflamed arteries. To overcome the limitations in examining in situ T cells, we have used a human artery-severe combined immunodeficiency chimera model, in which vascular inflammation is induced in engrafted human arteries by reconstituting such chimeras with peripheral blood mononuclear cells (PBMCs) from patients with GCA. 6, 30 In this model system, alloantigens serve as model antigens to probe immunoregulatory defects in patients with GCA that are relevant for immune responses in the microenvironment of the vessel wall. Tofacitinib therapy was highly effective in suppressing vasculitogenic immunity by inhibiting the clonal expansion of wall-residing T cells. 
METHODS
All data supporting this study's findings are available from the corresponding author on request.
Patients and Tissue Samples
Temporal arteries were collected from diagnostic biopsies. GCA was diagnosed based on typical histological findings. 2 Noninflamed human axillary arteries free of wall-infiltrating T cells and macrophages derived from tissue donors (12-18 hours postmortem). Patients with a tissue diagnosis of GCA and active disease donated blood for the study. The Stanford Blood Bank Research Program supplied age-and sex-matched healthy controls. Preexisting cancer, autoimmune disease, or chronic viral infection were exclusion criteria. The clinical characteristics of the patients in this study are summarized in the Table. PBMCs were isolated by density-gradient centrifugation (Lymphoprep). Naive CD4 + T cells were purified by negative selection (EasySep naive CD4 + T-cell enrichment kits, STEMCELL Technologies).
Human Artery-Severe Combined Immunodeficiency Mouse Chimeras
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were purchased from Jackson Laboratory. Human artery-mouse chimeras were generated as published. 6, 31 Normal temporal or axillary arteries were cut into rings (3 mm) and engrafted into a midline subcutaneous pocket of the mice. Six days later, mice received 10 µg of lipopolysaccharide. The next day, PBMCs (1×10 7 ) from a patient with active GCA or an agematched healthy individual were adoptively transferred into each mouse.
For model validation, we compared the induction of vessel wall inflammation after transfer of PBMCs from agematched controls or patients with GCA into artery-engrafted NSG mice ( Figure I in the online-only Data Supplement). Transferred human cells establish organized lymphoid structures in the murine spleen. 32 Spleen/body weight ratios were similar in mice receiving control or patient-derived PBMCs ( Figure IA in the online-only Data Supplement), indicating similar immunoreconstitution of paired mice carrying the same arterial tissue, but receiving healthy or GCA PBMCs. Numbers of transferred human cells were chosen such that allogeneic recognition of arterial cells was avoided. To detect even subtle inflammation in the artery grafts, marker gene transcripts were monitored in the tissue transcriptome of explanted grafts (n=10 each from control PBMC or GCA PBMC-reconstituted mice). Based on tissue transcripts for the monocyte/macrophage marker CD163 and the dendritic cell marker CD83, only patient-derived PBMCs were successful in inducing inflammation ( Figure IB and IC in the onlineonly Data Supplement). As expected, arterial grafts were free of transcripts for T-cell receptor, T-bet, and IFN-γ in the absence of human PBMCs. No signal for tissue-infiltrating T cells was recorded in mice reconstituted with control PBMC, but GCA-PBMC produced robust T-cell infiltrates ( Figure ID in the online-only Data Supplement). Vascular endothelial growth factor (VEGF) is an excellent marker of endothelial cell activation and neoangiogenesis in GCA. 31 Tissue VEGF transcripts were indistinguishable in grafts from PBMC-free mice and control-PBMC-reconstituted mice, but were upregulated in the presence of patient-derived PBMC ( Figure IE in the online-only Data Supplement). 
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To examine the impact of the artery graft on immune reconstitution, NSG mice were assigned to parallel treatment arms: arm 1 received an artery as in Figure I in the onlineonly Data Supplement; arm 2 was sham operated. Mice were immune-reconstituted with 1×10 7 GCA PBMCs. Immune reconstitution was assessed after 7 days in the chimeras' spleen and circulating blood. Human T cells were quantified by flow cytometry of CD45 + CD3 + cells ( Figure II in the onlineonly Data Supplement).
Tofacitinib Treatment
Mice carrying arterial tissue from the same donor and immunoreconstituted with PBMCs from the same patient were randomly assigned to the vehicle or tofacitinib-treatment group. Tofacitinib dosing was assessed in pilot experiments to avoid T-cell and monocyte cytopenia. 33 In experiments shown here, mice received 3 mg/kg tofacitinib or an equal volume of vehicle orally daily over 1 to 2 weeks as indicated. 34 Grafts were harvested at the end of the experiment, snap-frozen for RNA isolation, or OCT-embedded for hematoxylin and eosin and immunostaining. To prepare single-cell populations, explanted spleens or arteries were minced into pieces and incubated with collagenase I (2 mg/mL) and DNase (40 U/mL) at 37°C. Cells were filtered through a cell strainer to prepare single-cell suspensions.
Statistics
Statistical analysis was performed using GraphPad Prism 5.0. All data are expressed as mean±SEM, and P<0.05 was considered statistically significant. Populations were compared using the t test or Wilcoxon test as appropriate. To adjust for multiple testing, in addition to individual P values, we used the Hochberg step-down method to control for a family-wise error rate at the 0.05 level. To assess interventions, we applied the paired t test or paired Wilcoxon test. The Wilcoxon test was used for robustness when the sample size per group was >5. Where appropriate, 1-way ANOVA was used and pairwise comparison using the Tukey method to adjust for multiple testing was applied.
Study Approval
All procedures and biospecimen collections were approved by the Institutional Review Board and informed consent was obtained as appropriate. The animal protocol was approved by the Animal Care and Use Committee.
Additional methods available in the online-only Data Supplement. Polymerase chain reaction primers are listed in Table I in the online-only Data Supplement.
RESULTS

Expression of STAT Target Genes in GCAAffected Arteries
Temporal arteries with the typical granulomatous lesions of GCA are a cytokine-rich tissue environment, 35 with a multitude of innate and adaptive effector molecules. Th1-cell-derived IFN-γ is a critical disease driver, 36, 37 but less is known about tissue concentrations of other adaptive and innate cytokines, including IL-21, IL-1, IL-6, and tumor necrosis factor-α. In search for clues for which cytokines may be key activators in GCA arteries, we made use of the fact that many cytokines signal through JAK/STAT pathways to mediate their proinflammatory functions. To support the concept that selected JAK-STAT signaling pathways are particularly relevant for GCA inflammation, we evaluated the expression of selected STAT target genes ( Figure 1A ). STAT1-and STAT2-dependent target genes (T-bet, CXCL9, ISG15, OAS1) were strongly upregulated in the vasculitic arteries. Target genes induced by STAT3, STAT5a, and STAT6 signaling were consistently low, indistinguishable from normal, noninflamed temporal arteries ( Figure 1A ). Typically, each of the STAT family members is a target gene induced when the respective transcription factor is activated. 17 Thus, we quantified transcripts for STAT1, STAT2, STAT3, STAT4, STAT5a, and STAT6 in 8 diagnostic biopsies from GCA-affected and 8 noninflamed specimens ( Figure 1B through 1G ). Transcripts for all STAT family members were at low abundance in normal arteries, and STAT3, STAT5a, and STAT6 remained sparsely expressed in GCA-affected arteries. In contrast, STAT1, STAT2, and STAT4 transcripts were abundantly present in vasculitic arteries ( Figure 1B through 1D ). After adjustment for multiple testing using the Benjamini-Hochberg method, the STAT1 increase remained statistically significant. STAT1 and STAT2 are the key transcription factors triggered by IFNs, with type I IFNs activating STAT1/2 heterodimers and IFN-γ activating STAT1 homodimers. 38 We examined the tissue transcriptome of noninflamed and inflamed arteries for IFN-α, IFN-β, and IFN-γ transcripts ( Figure 1H through 1J) and found significantly elevated concentrations of IFN-α-and IFN-γ-specific sequences, suggesting that both type I and II IFNs are actively participating in the vasculitic lesions. The STAT4 target gene furin and STAT4 transcripts were borderline elevated in vasculitic versus normal arteries. Target genes for STAT3 and STAT6 were distinctly low, questioning a role for IL-6 and IL-4 in the tissue microenvironment. The STAT5 target gene FOXP3 was barely detectable in the tissue transcriptome.
Albeit providing only indirect evidence, these gene expression data suggested the predominance of STAT1 and STAT1/2 activation events in GCA lesions, focusing attention on type I and type II IFNs.
IFN-γ Production in GCA T Cells Is Susceptible to the JAK/STAT Inhibitor Tofacitinib
Considering the predominance of STAT1 in the vasculitic infiltrates, we explored whether CD4 + T cells from
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patients with GCA are biased toward IFN-γ production and whether Th1 lineage commitment involves JAK3 activation. We stimulated CD4 + T cells from patients and age-matched controls under nonskewing conditions and tested whether Th1 commitment was sensitive to the JAK3 inhibitor tofacitinib (Figure 2 ). Because antigen-presenting cells were excluded from the cultures, stimulation conditions relied exclusively on T-cell receptor signaling. Tofacitinib preferentially suppresses signals dependent on cytokine receptors containing the γc-(IL-2, IL-4, IL-7, IL-9, IL-15, IL-21). 39 Over 6 days, an average of 18% of healthy CD4 + T cells became IFN-γ producers. Tofacitinib (30 nmol/L) decreased the proportion of Th1-lineage-committed cells to 13%, indicating that one third of the type II IFN-producing T cells depended on JAK/STAT-derived signals (Figure 2A and 2B ). CD4 + T cells from patients with GCA were spontaneously biased toward IFN-γ production. T-cell receptor activation induced intracellular IFN-γ stores in 25% of CD4 + T cells. A substantial proportion of these cells was susceptible to JAK/STAT inhibition, which reduced frequencies of IFN-γ + CD4 + T cells to 15% (Figure 2A and 2B ).
These data indicated that patients with GCA guide CD4 + T cells toward Th1 effector functions, specifically IFN-γ production, and that pharmacological inhibition of JAK3/1 effectively suppresses this abnormality.
Tofacitinib Inhibits Inflammatory Responses in the Vessel Wall
To investigate whether the pathogenic immune responses leading to vascular inflammation depend on γc-containing cytokine receptors, inflammation was induced in human arteries engrafted into NSG mice by immunoreconstituting such mice with PBMCs from patients with GCA ( Figure 3) .
Vessel wall infiltrates were markedly reduced in tofacitinib-treated grafts ( Figure 3A) . The density of tissue-infiltrating CD3 + T cells especially declined. The concentration of T-cell receptor transcript was consistently lower after blockade of γc-containing cytokine receptors. In a series of 8 independent experiments, numbers of tissue-residing T cells reached 51.00±6.2 per high-powered field and declined to 22.7±3.3 per high-powered field in tofacitinib-treated mice (Fig- Figure 3D ). We examined whether JAK3/1 blockade affected recruitment and retention versus in situ expansion of tissue-infiltrating T cells (Figure 3E and 3F ). Tissue-residing T cells were highly proliferative in vehicle-treated arteries. About 40% of tissue-residing CD3 T cells expressed the proliferation marker Ki-67, suggesting that clonal expansion contributes significantly to the formation of the intramural lesions. As JAK3-dependent signaling was disrupted with tofacitinib treatment, <10% of tissueentrapped T cells were dividing ( Figure 3F ). Tofacitinib's antiproliferative effect was not restricted to T cells recruited to the vessel wall. Human T cells in the blood and in the murine spleen also declined, implicating γc To understand how suppression of T-cell growth affects T-cell effector functions at the site of tissue inflammation, we analyzed gene expression patterns for lineage-determining transcription factors (T-bet, RORC, Bcl-6, FOXP3), and transcripts for the T-effector cyto- 
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kines IFN-γ, IL-17, and IL-21. Th1, Th17, and T follicular helper cells have all been localized to the vasculitic lesions and have been implicated in tissue-damaging inflammation. 40 Tofacitinib treatment left expression of FOXP3 transcripts unaffected, but reduced concentrations of T-bet, RORC, and BCL-6 by >40% (Figure 4) . The immunosuppressive effect of the JAK3 inhibitor was even more pronounced for effector cytokines. IFN-γ and IL-17 mRNA were reduced to minimal levels, and IL-21 mRNA declined by 58% (Figure 4) .
Taken together, γc function appears critical in the pathogenic cascade of vascular inflammation, and JAK1/3 inhibition effectively interferes with the expansion of granulomatous lesions and the prosurvival signals produced in the tissue microenvironment.
Tissue-Resident T RM Require JAK1/3 Function to Survive
T RM cells have recently been recognized as a transcriptionally, phenotypically, and functionally distinct lymphocyte lineage, distinct from classical memory T cells. 41 Specialized to keep residency in the tissue microenvironment, T RM cells are believed to provide fast and effective immune responses when reencountering antigens. 11 Expression of the αE integrin CD103, which combines with the integrin β7 to form the ligand for E-cadherin, has been mechanistically linked to tissue anchoring. 42 Given their persistence in peripheral tissues, T RM cells are considered essential pathogenic elements in chronic inflammatory disease. 10 In support of the concept that intramural vasculitic foci contain + T cells that was essentially exclusively present in the arterial wall and was barely detectable in the peripheral blood ( Figure 3G and 3H and Figure V in the online-only Data Supplement). This population of CD4 T RM was highly sensitive to tofacitinib, implicating γc-signaling cytokines in its survival.
To further study T RM in vasculitic lesions, we developed a transengraftment model, in which arterial inflammation was first induced in engrafted human arteries, before they were transplanted into an empty NSG mouse ( Figure 5A ). This model system avoided competition between continuous recruitment of new T-cell specificities into the vessel wall with T cells residing and proliferating in the lesion. Following the removal from a continuous T-cell supply, the arterial wall infiltrates maintained high proliferative activity, the density of tissue-invading T cells grew, and the expanding T-cell populations moved deeper into the vascular wall layers ( Figure 5B and 5C) . A subset of 5% to 8% of T cells acquired expression of the CD103 marker, as identified by flow cytometric analysis of cells isolated out of the human arteries ( Figure 5G and 5H) . About 25% of the tissue-residing T cells were Ki-67-positive, identifying them as dividing cells ( Figure 5E and 5F). Over a period of 2 weeks, the number of T cells seen in tissue sections doubled (Figure 5C and 5D) . Growth in the vasculitic infiltrates was associated with a 2-to 3-fold increase in the expression of transcripts specific for T-bet, RORC, IFN-γ, IL-17, and IL-21 ( Figure 5I ). If the empty NSG mice engrafted with the already inflamed arteries were treated with a daily oral dose of tofacitinib (3 mg/kg), the density of tissueinfiltrating T cells declined markedly, returning to levels seen in nontransplanted arteries ( Figure 5C and 5D ). In parallel, accumulation of cytokine-producing T cells was effectively stopped, as demonstrated by the marked reduction in T-bet, RORC, IFN-γ, IL-17, and IL-21 mRNA ( Figure 5I ). Most importantly, tofacitinib effectively disrupted survival signals for CD4 + CD103 + T RM cells, which sank to low frequencies in artery grafts treated with the Jakinib (Figure 5G and 5H) .
To examine whether the microenvironment of the inflamed arterial wall is permissive to support the induction and survival of T RM , we searched for the presence of IL-7, IL-9, and IL-15 in the tissue microenvironment ( Figure VI in the online-only Data Supplement), because these cytokines have been implicated in supporting T RM . 43 Induction of vessel wall inflammation was associated with significant upregulation of IL-7, IL-9, and IL-15 ( Figure VIA through VIB in the online-only Data Supplement), supplying critical ingredients for local Tcell persistence and growth.
In essence, T RM cells in the inflamed vessel wall require JAK3/1-dependent signaling to survive, and inhibiting the kinase activity appears to be an effective strategy in halting vasculitogenic immune responses. 
Jak3-STAT Signaling Drives InflammationAssociated Microangiogenesis in the Inflamed Vessel Wall
When affected by GCA, large and medium arteries develop a dense network of microvessels, leading to adventitial thickening and giving rise to the enhancement effect on imaging studies. 1 Newly formed microvessels are identified by tissue stains for α-smooth muscle actin (α-SMA)-expressing pericytes and von Willebrand factor-positive endothelial cells. 6 Adventitial vasa vasorum are present in healthy, noninflamed arteries (Figure 6A, left) and remained essentially unchanged if arteries were engrafted into mice lacking patient PBMC ( Figure 6A center and 6B) . Induction of vasculitic wall infiltrates in PBMC-reconstituted chimeras was associated with robust neoangiogenesis ( Figure 6A right and 6B), indicating the critical role of the donor immune cells in the process of neoangiogenesis. The numbers of microvessels identified by immunostaining in tissue sections were >10-fold higher in arterial grafts after successful induction of transmural inflammation (Figure 6B) .
To explore whether γc-dependent signaling had a role in this damage-associated pattern, chimeras with inflamed human arteries were assigned to a vehicle or a tofacitinib treatment arm (Figure 6C through 6E) . Grafts explanted from vehicle-treated animals had dense networks of newly formed microvessels ( Figure 6C) , and tissue-extracted RNA contained high transcript levels for the angiogenic factors platelet-derived growth factor, fibroblast growth factor 2, and VEGF ( Figure 6E ). Inhibition of JAK3 activity with tofacitinib robustly suppressed the neoangiogenic response. Numbers of microvessels were <50% of those in the vehicle control arteries ( Figure 6C and 6D ). Tissue concentrations of Figure 6 . Tofacitinib inhibits inflammation-associated microangiogenesis. Human artery-SCID chimeras were generated as in Figure 3 and treated with vehicle or tofacitinib (3 mg/kg per day) as described above. Explanted arteries were analyzed for microangiogenesis by immunofluorescence staining of α-SMA, vWF, and DAPI. Gene expression was quantified by RT-PCR. A, Representative images of α-SMA + vWF + adventitial microvessels. Left, healthy medium-sized artery; Middle, artery explanted from mice that did not receive human PBMCs; Right, artery explanted from chimeras that were immunoreconstituted with GCA PBMCs (scale bar=200 µm). B, Quantification of adventitial microvessels (n=4 each; comparison by t test). C and D, α-SMA + /vWF + microvessels in vehicle and tofacitinib-treated grafts. Representative images (scale bar=200 µm) and microvessel density in paired arterial grafts. Paired Wilcoxon test applied. E, Tissue gene expression of angiogenic cytokines in vehicle and tofacitinib-treated explants. Paired arterial grafts are line connected. *P<0.05, **P<0.01, ***P<0.001 by paired Wilcoxon test. DAPI indicates 4ʹ,6-diamidino-2-phenylindole; FGF2, fibroblast growth factor 2; GCA, giant cell arteritis; HPF, high-power field; ns, not significant; PBMC, peripheral blood mononuclear cell; PDGF, platelet-derived growth factor; RT-PCR, reverse transcription polymerase chain reaction; SCID, severe combined immunodeficiency; α-SMA, α-smooth muscle actin; VEGF, vascular endothelial growth factor; and vWF, von Willebrand factor.
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transcripts specific for platelet-derived growth factor, fibroblast growth factor 2, and VEGF ( Figure 6E ) were strongly tofacitinib-responsive. These experiments implicated signaling through the γc in the disease-relevant process of microangiogenesis, which supplies oxygen and nutrients to the thickening arterial wall and the expanding intimal layer. The Jakinib tofacitinib was sufficient to arrest the neoangiogenic program, in support of a direct role for activated T cells in the growth of new vasa vasora.
JAK1/3-STAT Signaling Promotes Intimal Hyperplasia
The ischemic complications of GCA, above all the ischemic damage to the optic nerve, result from arterial stenosis/occlusion, caused by fast and concentric intimal hyperplasia. 44 Induction of transmural inflammation in engrafted human arteries was associated with high proliferative activity in vascular cells, in both the media and the intima, leading to growth of the intimal layer (Figure 7A and 7B). Over a disease period of 2 weeks, the tunica intima grew to a thickness of 30 to 40 µm, equivalent to 15 to 20 cell layers. Proliferative activity was encountered in 2 cellular populations: (1) cells expressing the smooth muscle cell/fibroblast marker α-SMA, which were enriched in the adventitia and intima; and (2) α SMA -negative cells localized within the immune cell infiltrates and centering on the media ( Figure 7C and 7D). Such proliferating α-SMA-negative cells represent T cells and macrophages (Figure 3) . Tofacitinib treatment essentially curbed the proliferative activity of all dividing cell populations ( Figure 7C and 7D) . The hyperplastic reaction of the intima was aborted; thickness measurements fell from 35 to 10 µm ( Figure 7A and 7B). The antiproliferative effect of tofacitinib equally affected α-SMA-expressing vascular cells and infiltrating immune cells, which may reflect direct and indirect inhibition of growth signals. Few dividing cells remained in the arteries treated with tofacitinib ( Figure 7C and 7D) .
These data connected γc cytokine responses to the damage pattern of intimal hyperplasia. Blocking Jak3-STAT signaling suppressed proliferative activity of immune and nonimmune cells, successfully protecting the vascular wall from inflammation-induced remodeling. 
DISCUSSION
GCA is a prototypical large vessel vasculitis, caused by vasculitogenic T cells and macrophages building organized lymphoid microstructures in the otherwise immunoprivileged niche of the vessel wall. Long-lived T cells coordinate effector functions of accompanying macrophages, and vessel wall cells react with a maladaptive repair response, ultimately promoting vascular failure. Acutely, GCA is treated with high-dose corticosteroids, which suppress nonspecific innate immunity, but spare the multifunctional T cells trapped in the lesions. 2, 40 Persistent functional activity of lesional T cells creates smoldering vasculitis, the ultimate challenge in the management of affected patients.
Here, we have characterized the proliferative capacity of the vasculitogenic T cells and have identified CD4 Early studies in GCA temporal arteries emphasized the sharing of T-cell receptor sequences in physically separated vasculitic foci, compatible with antigendriving lesional T cells. However, the concept of a single vasculitogenic autoantigen has recently been replaced by a disease model that focuses on the antigen-nonspecific defects driving vasculitis. The emerging paradigm recognizes broad immunoregulatory defects in GCA, indicative of T-cell hyperreactivity because of an altered activation threshold setting. Hyperreactive T cells in patients with GCA result from failed immune checkpoints that control the response to many antigens. Specifically, NOTCH1 + CD4 + T cells in GCA patients receive activating signals from Jagged1 + microendothelial cells in the arterial adventitia. 31 Also, a defect in the immunoinhibitory PD-1 checkpoint enables unopposed T-cell activity in the vascular lesions. 6 Patients' CD4 + T cells are insufficiently suppressed because of the failure of immunoinhibitory CD8 T regulatory cells. 45 These data emphasize the importance of the tissue environment in enabling inappropriate T-cell immunity and reveal abnormalities in T-cell responsiveness that are applicable to a broad spectrum of antigens. Which antigens are recognized in the human artery-severe combined immunodeficiency mice is not known, but alloantigens serve as model antigens to probe T-cell reactivity in GCA. Insufficient control of a broad range of adaptive immune responses in patients with GCA appears best matched by therapeutically targeting the T cell's signaling machinery, in line with the anti-inflammatory effects of the JAK1/3 inhibitor tofacitinib demonstrated in the current study.
Several lines of evidence support the concept that IFNs, including type I (IFN-α/β) and type II (IFN-γ) are of particular relevance in GCA. IFN-α/β and IFN-γ trigger JAK-STAT signaling, with both types of IFN activating STAT1.
46 STAT2 functions as a transcription factor for type I IFN-dependent responses. 47 The tissue transcriptome of GCA-affected arteries contained a signature indicative for in situ IFN responses; IFN-α and IFN-γ transcripts were significantly increased, target genes for STAT1 (T-bet, CXCL9) and STAT2 (ISG15, OAS1) were enriched, and STAT1 and STAT2 were selectively upregulated, supporting the pinnacle role of T cells in the disease process. The IFN-γ-rich environment provides ideal conditions for highly activated and functionally diverse macrophages arranged in the typical granulomatous infiltrates. 37 How this IFN-γ-rich environment promotes other disease components, especially the formation of new blood vessels and the hyperplasia of the intima, is more difficult to understand. The current paradigm holds that both types of IFN are anti-angiogenic. Previously, macrophages and multinucleated giant cells were identified as the producers of the angiogenic factor VEGF in GCA-affected temporal arteries. 48 Indeed, in temporal artery biopsies, tissue IFN-γ and VEGF were strongly associated with the degree of intramural vessel formation, demonstrating that, in this vasculitis, IFN-γ promotes, not suppresses, neoangiogenesis. 48 Unexpectedly, STAT3 target genes were at low abundance in the temporal artery biopsies, questioning the in situ action of IL-6, which may function mostly in extravascular sites. Also, the low expression of STAT6 target genes is in line with a lack of IL-4 production in GCA lesions. 49 The current treatment paradigm in GCA is the use of corticosteroids, which preferentially target innate cytokines, such as IL-1β, IL-12, and IL-6, 3 but have little effect on tissue-residing T cells. 2, 36 Therapeutic needs therefore lie in eliminating the T-cell infiltrates. Functionally, lesional T cells are highly diverse, 40 but the data presented here indicate that they depend on common survival signals. Inflamed arteries were rich in T-cell growth and survival cytokines ( Figure VI in the online-only Data Supplement), and inhibiting the activity of JAK1/3 was sufficient to broadly diminish lineage-determining transcription factors (T-bet, RORC, and BCL-6) and T-cell effector molecules (IFN-γ, IL-17, and IL-21). Tofacitinib minimized the in situ proliferation of lesional T cells, and flow cytometric analysis confirmed that the T-cell-suppressive effect of disrupting JAK-STAT signaling included CD4 + CD103 + T RM . Tofacitinib's powerful immunosuppressive effect is encouraging, because it may be able to disrupt upstream pathogenic drivers and turn the disease from a long-lasting wall inflammation into an acute and treatable condition. Tissue-resident T RM have recently been described as a specialized T-cell subset defined by its exquisite ability to anchor in peripheral tissues instead of returning to secondary lymphoid organs. For protective immunity, T RM cells provide fast and locally effective protection. For vasculitogenic immunity, such T cells may hold the key to chronicity and persistent wall injury, even after good control of peripheral inflammatory markers has been reached. We confirmed the tissue residence of CD4 + CD103 + T cells by transengrafting inflamed arteries into empty mice, making vascular lesions the sole reservoir for human cells. CD4 + CD103 + T cells were explicitly infrequent in the periphery, but populated the transmural vascular lesions. Besides their role in driving chronic vascular inflammation, T RM cells may provide important clues on pathogenic principles in inflammatory vasculopathies. In the vascular tree, GCA is characterized by stringent tissue tropism. Parameters defining the susceptibility of certain arteries to the disease, while others are protected, have not been identified. The ascending aorta, the aortic arch, the distal subclavian arteries, and the temporal arteries are particularly susceptible. Considering the critical role of T RM in driving persistent inflammation, the local microenvironment may dictate the survival of T RM . In this model, nonpermissive microenvironments would protect the immunoprivilege of many arterial walls by failing to support the persistence of tissue-residing T RM . Molecular definition of such microenvironmental niches could greatly enhance our understanding of the disease process.
In conclusion, persistence of vessel wall inflammation in medium and large vessels appears to be dependent on a small population of highly specialized T cells, characterized by their ability to survive in the tissue microenvironment. The longevity of such CD4 + CD103 + T RM cells requires cytokine signals that are mediated through the common γc, rendering such T RM susceptible to kinase inhibitors that can disrupt γc-dependent signaling. Depletion of such CD4 + CD103 + T RM cells was sufficient to inhibit a cascade of pathogenic events: the production of effector cytokines (IFN-γ, IL-17, and IL-21), the formation of inflammation-induced microvascular networks, and the expansion of the intimal layer. The JAK inhibitor tested here is approved for treatment of patients with rheumatoid arthritis and has been shown to have acceptable toxicity risks. 50 Targeting dysregulated T cells instead of suppressing innate immunity (eg, through corticosteroids) promises to fulfill a gap in the management of patients with vasculitis, while also providing informative insights into basic immune abnormalities of patients with aortitis and medium-vessel vasculitis.
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